BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20210527T190000
DTEND;TZID=Africa/Nairobi:20210527T203000
DTSTAMP:20260424T071253
CREATED:20210530T161355Z
LAST-MODIFIED:20211024T153904Z
UID:5219-1622142000-1622147400@kesho-kenya.org
SUMMARY:HR+/HER2-Ve Advanced Breast Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Prof Alice Musibi\, Assistant Professor and Medical Oncologist\, Kenyatta National Hospital \nSponsor: Novartis \nPresenters: \n\nDr. James Mbogo\, clinical oncologist working with Dr. Vj Oncology Associates based at the Nairobi West Hospital.\n\nTreatment choice for advanced breast cancer should take into account hormone receptor and HER-2 status and germline BRCA status of the patient\, in addition to PIK3CA in HR+ and PD-L1 in TNBC patients. It’s important to consider the accessibility of targeted therapies\, previous therapies\, and their toxicities. Other important factors to consider include tumor burden\, biological age\, comorbidities\, menopausal status\, need for rapid disease/ symptom control\, socioeconomic and psychological factors\, available therapies\, and patients preference. Endocrine-based therapy is preferred for hormone receptor-positive disease in patients with visceral disease. The presence of visceral crisis as a result of severe organ dysfunction can be determined by signs and symptoms\, laboratory studies\, and rapid progression of the disease. Its presence implies important visceral compromise; a clinical indication for a more rapidly efficacious therapy\, particularly because another treatment option at progression will probably not be possible. For pre-menopausal women for whom endocrine therapy was decided\, ovarian suppression/ablation (through surgery and radiation) combined with additional endocrine-based therapy is the preferred choice. Primary and secondary endocrine resistance after endocrine therapy is associated with various mechanisms. A CDK4/6 inhibitor combined with endocrine therapy is the standard of care for patients with ER+/HER-2 negative advanced breast cancers. The body composition parameters may influence prognosis in patients receiving CDK4/6 inhibitors\, whose side-effects include bone marrow toxicities\, liver enzymes\, fatigue\, pain\, skin toxicities (rashes)\, vomiting\, and neutropenia.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/hr-her2-ve-advanced-breast-cancer/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2021,Webinar Recording Available
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/05/HRHER2-ve-Advanced-Breast-Cancer.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20210520T190000
DTEND;TZID=Africa/Nairobi:20210520T203000
DTSTAMP:20260424T071254
CREATED:20210530T163719Z
LAST-MODIFIED:20211024T153911Z
UID:5226-1621537200-1621542600@kesho-kenya.org
SUMMARY:Updates in the Management of Neuroendocrine Tumors
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Njoki Njiraini\, Resident Clinical and Radiation Oncologist at The Nairobi Hospital. Sponsor: Novartis Presenters: \n\nDr. Primus Ochieng\, Programme Director of MMed Radiation Oncology training at the University of Nairobi. He is both a Lecturer and a Consultant Clinical Oncologist at Kenyatta National Hospital\n\nNeuroendocrine tumors (NET) are a common malignant transformation of cells in the diffuse neuroendocrine system that regulates motility and secretion. The tumors are heterogeneous with a wide variety of clinical presentations and are difficult to diagnose. Neuroendocrine carcinomas are poorly differentiated with increased expression of Ki67. Most patients present with advanced disease and have a median survival of 33 months. NETs are distributed all over the body. Over 95% of NET is sporadic\, with only a small percentage being genetic-related. Currently\, there are no preventive strategies and no screening guidelines. Initially\, the classification of NET was based on the tissue of origin. To date\, WHO classification is based on grading and staging. Classification can also be based on functioning versus Non-functioning NET. Presentation is by tumor growth with pain\, obstruction hepatomegaly\, and early satiety. Diagnosis is by a systematic approach including history and physical examination\, biochemical markers\, and imaging\, although conventional imaging has a limited role in diagnosis. Chromogranin A (CgA) is a valuable diagnostic and prognostic tool that can be used to monitor treatment response. It is more sensitive than radiology for measuring progression. The major challenge with this testing method is that other conditions can cause elevated CgA and also the CgA values vary considerably between different types of NETs. The test kits are also not universally standardized. Therapies for NETs apply three principles: surgical therapy\, (best treatment option)\, symptomatic therapy\, and anti-proliferative therapy. The current focus is shifting from symptom management to targeting tumors. Chemotherapy including temozolomide and capecitabine has been shown to improve overall survival benefits\, better response\, and progression-free survival. Considering immunotherapies\, Pemblolizumab has benefits in NET tumors. Radiotherapies have palliative use. Although NETs are well managed with targeted therapy\, the technology is not currently available in Kenya. Considering limited available data\, there is a need to work in groups and generate local data on NETs.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-neuroendocrine-tumors/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2021,Webinar Recording Available
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/05/Management-of-Neuroendocrine-Tumors.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20210513T190000
DTEND;TZID=Africa/Nairobi:20210513T203000
DTSTAMP:20260424T071254
CREATED:20210530T171047Z
LAST-MODIFIED:20211024T153919Z
UID:5235-1620932400-1620937800@kesho-kenya.org
SUMMARY:Chronic Myeloid Leukemia (CML) Treatment In Kenya
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Prof. N. A. O. Abinya\, Medical Oncologist\, the Nairobi Hospital and GIPAP Physician \nSponsor: Novartis \nPresenters: \n\nDr. Peter Oyiro\, Medical Oncologist Kenyatta National Hospital Teaching and Referral Hospital\n\nChronic Myeloid leukemia is a cancer of bone marrow stem cells. The only known risk factors are radiation from nuclear reactors\, with no evidence of heredity risk factors. It is characterized by a translocation between chromosomes 9 and 22\, which results in an abnormal juxtaposition of two genes\, bcr\, and abl. It accounts for 15% of all leukemia cases and has an annual incidence of 1.5 cases per 100000 individuals. The median age at diagnosis is 55-65 years\, with a median survival of 3-7 years. The clinical presentation is usually massive splenomegaly\, where the disease has three phases: chronic\, accelerated\, and blast. Most patients are diagnosed in the chronic phase\, often without symptoms.  If untreated\, all patients progress to the accelerated/blast phase within 3-5 years. Diagnosis is by physical examination of the spleen and liver size\, complete blood cell count\, bone marrow aspirate for cytological examination and cytogenetic\, fluorescence in-situ hybridization\, reverse transcriptase-polymerase chain reaction (RT-qPCR). Late referrals\, inadequate infrastructure\, and trained physicians are major challenges to diagnosis. The life expectancy of newly diagnosed patients with CML in the chronic phase is now very close to age-matched individuals in the general population of Western countries. In resource-constrained countries e.g. Kenya\, the goal of treatment remains survival. The Glivec International Patient Assistance Program (GIPAP) is an international drug donation program established by Novartis Pharma AG and implemented in partnership with the Max Foundation. It has provided imatinib to eligible patients in Kenya since 2002\, at the Nairobi and the Aga Khan Hospitals for free. Patients with CML diagnosis can be referred to the GIPAP. Before imatinib was approved (FDA 2001)\, most patients were being treated with supportive care\, hydroxyurea\, interferon\, and allogeneic hematopoietic cell transplantation (“bone marrow transplant”). Today\, CML management in Kenya is mainly based on imatinib. Those failing therapies are put on second and third-generation TKIs. It’s important to check on kinase mutations that confer resistance to kinase inhibitors. Patients resistant or intolerant to imatinib can be treated with nilotinib. The main goal of treatment is to reduce the leukemic burden and the risk of progression to AP or BC. However\, if the warning signs are not recognized early\, treatment can be either a success or a failure. Molecular responses such as MMR are associated with improved survival outcomes. The major challenge with treatment is the unavailability of some drugs and high prices. Due to the COVID-19 pandemic\, there is a switch from physical to virtual review of files. The pandemic has greatly affected adherence and compliance to treatment.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cml-treatment-in-kenya-successes-challenges/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2021,Webinar Recording Available
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/05/CML-Treatment.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20210506T190000
DTEND;TZID=Africa/Nairobi:20210506T203000
DTSTAMP:20260424T071254
CREATED:20210810T102601Z
LAST-MODIFIED:20220314T124351Z
UID:5238-1620327600-1620333000@kesho-kenya.org
SUMMARY:Optimizing Cancer Research in Kenya
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nModerator: Dr. Veronica Manduku\, Radiologist at Kenya Medical Research Institute \nSponsor: Roche \nPresenters: \n\nProf. Mansour Saleh\, Chair\, Department of hematology and oncology and consultant medical oncologist\, Aga Khan University Hospital\, Nairobi.\nProf. Fredrick Chite\, CEO/Executive Director of International Cancer Institute (ICI)\nProf. N.A.O. Abinya\, Medical Oncologist\, the Nairobi Hospital and GIPAP Physician\nDr. Robai Gakunga\, Independent Research Scientist\, USIU-Africa\n\nCancer research in Kenya is mainly in the universities and is more of epidemiological studies with limited clinical research. Considering the increasing demand for cancer research in Kenya\, there is a need to develop a curriculum\, build capacity and create infrastructures to support quality research. Many drugs used in Africa are not tested in Africa\, despite research showing variations in transcriptomics for example in triple-negative breast cancer for different races. Cancer research requires a multidisciplinary approach (MDT). Funding is a major challenge in cancer research. Additionally\, managing clinical practice and research becomes difficult in Kenya where clinicians are expected to spend 100% of the time in practice\, unlike in the USA\, where there is the flexibility of working hours. In the USA\, a clinician can spend 50% of the time in clinical practice and 50% in research. In Kenya\, the workloads for doctors\, clinicians\, and lecturers are overwhelming\, with no protected time for research from the institutions. In-Africa collaborations\, as opposed to Africa-America\, and networks between clinicians\, consultants\, academic institutions\, and government agencies\, would greatly help to generate local data. Data sharing and Trust is needed and the ability to work together to accomplish a goal. The University of Nairobi has an oncology training fellowship that is helping to build capacity in the region. Commitment in science for clinicians as well as developing and reviewing protocols collectively is necessary. Considering the high cost of cancer drugs\, cancer clinical trials should seek collaborations with pharmaceutical companies. Community and patient engagement are important in clinical trials. There is a need for a data repository and registries. There is an epidemiological registry in breast cancer collected at Kenya National Hospital in collaboration with Roche. Collaborations will facilitate sharing of human resources\, infrastructure\, and samples. The literature review is equally important. The exchange program for fellows helps with gaining experience to see what other researchers are doing. Scientists are encouraged to apply for research grants\, however small. There is a need for seed funds for young investigators. Government-government collaborations are also encouraged. Research governance is necessary. in lobbying government funding\, in priority areas including the most prevalent cancers (breast cancer in women\, prostate cancer in men). \n. \n[/vc_column_text]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/optimizing-cancer-research-in-kenya/
CATEGORIES:CME 2021,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210811_132731.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20210429T190000
DTEND;TZID=Africa/Nairobi:20210429T203000
DTSTAMP:20260424T071254
CREATED:20210810T095134Z
LAST-MODIFIED:20211024T153933Z
UID:5833-1619722800-1619728200@kesho-kenya.org
SUMMARY:Testicular Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Peter Oyiro\, Medical Oncologist Kenyatta National Hospital Teaching and Referral Hospital \nSponsor: Glenmark \nPresenters: \n\nDr. Amina H. Kidee\, Medical Oncologist Aga Khan University Hospital\nDr. Carnjini Yogeswaran\, Consultant Urological Surgeon\, Aga Khan University Hospital\n\nTesticular cancer (TC) accounts for less than 1% of adult neoplasms and 5% of urological tumors.  It’s the most commonly diagnosed cancer in young men (20-34 years)\, and the incidence is increasing in industrialized countries.\, but there is a need for local data to determine incidence in Africa. It is predicted that the survival rate in Kenya is low since the disease is not diagnosed early.  The risk factors for TC oncogenesis include cryptorchidism\, history of subfertility\, contralateral history of testicular cancer\, history of germ cell neoplasm in situ\, family history of TC\, race\, age\, and HIV. Individuals at high risk should be informed about the importance of physical self-examination. WHO classification of TC is based on the tumor origin\, and the presentation may be localized or disseminated. Diagnosis is by history\, examination\, imaging\, and serum tumor markers used for prognosis and staging.  Transcrotal ultrasound with Doppler is performed to confirm a testicular mass\, to determine whether a mass is intra or extra testicular\, and to explore the contralateral testis. Transscrotal biopsies of the testes should not be performed because of the risk of tumor cells seeding of the inguinal and pelvic lymphatic drainage. The biopsy is also of limited value because testicular germ cell tumors are heterogeneous. Management of the disease requires an integrated multidisciplinary team (MDT). Removal of the entire organ is necessary to properly identify the histologic type(s) present and to select the appropriate therapy. Radical inguinal Orchidectomy is the standard of care and involves the division of the spermatic cord at the internal inguinal ring. The scrotal approach should be avoided. Chemotherapy should be initiated prior to orchidectomy where applicable\, to control the disease and stabilize the patient. Testis sparing surgery aims to preserve fertility and hormonal functions. Patients should be counseled and be informed of the risk of local recurrence which is 8%. The testicular prosthesis should be offered to all patients undergoing unilateral or bilateral orchidectomy. It can be inserted at orchidectomy or subsequently. Contralateral testicular biopsy should be offered to high-risk patients. Semen abnormalities occur in 24-50% of TC patients even prior to orchidectomy. Additionally\, chemotherapy and radiotherapy can impair fertility. Semen preservation by sperm banking (cryopreservation) should be offered to all patients.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/testicular-cancer/
CATEGORIES:CME 2021,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210811_132749.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20210318T190000
DTEND;TZID=Africa/Nairobi:20210318T203000
DTSTAMP:20260424T071254
CREATED:20210810T093714Z
LAST-MODIFIED:20211024T153940Z
UID:5829-1616094000-1616099400@kesho-kenya.org
SUMMARY:Rectal Cancer – Multidisciplinary Approach
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Njoki Njiraini \nSponsor: Roche \nPresenters: \n\nDr. Anthony Ndiritu\, Consultant Clinical Oncologist\, Kenyatta National Hospital (KNH)\nDr. Alex Muturi\, Consultant General Surgeon & Endoscopist\, Kenyatta University Teaching Referral and Research Hospital (KUTRRH)\n\nManagement of colorectal cancer requires staging and risk assessment by a multidisciplinary team (MDT) to help in decision making and to audit and review the outcomes. Nutrition therapists are part of the MDT as the patients need to be nutritionally optimal before chemoradiotherapy and surgery for them to tolerate the effects of the treatment. Colorectal cancer is preventable and treatable if detected early. Early screening using immunochemical testing would help to pick the lesions when they are precancerous\, thus reducing cancer-related death by between 40-60%. A low index of suspicion of colorectal cancer among the caregivers is a major hindrance to timely diagnosis. For example\, patients with bloody stool may be treated for hemorrhage or other infections\, due to low suspicion of colorectal cancer. An accurate diagnosis would require a colonoscopy. Traditional\, extensive lymph node dissection with limited use of neoadjuvant radio is falling out of favor\, due to high functional genitourinary impairments and the need for experienced individuals to perform adequate dissection for outcomes. There is evidence that the dissection has similar recurrent rates as with neoadjuvant. Surgical site infections are a major challenge to surgery and require management. The cost of screening in Kenya is Ksh. 1000-2500. Management of colorectal cancer is by chemoradiation followed by surgery. The decision to take short-course radiotherapy (within a week) as opposed to the long course (5 to 6 weeks) should be guided by MDT. Patients with complete clinical response to chemoradiotherapy but who refuse to take surgery are at higher risk of local failure.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/rectal-cancer-multidisciplinary-approach/
CATEGORIES:CME 2021,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210811_132818.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20210311T190000
DTEND;TZID=Africa/Nairobi:20210311T203000
DTSTAMP:20260424T071254
CREATED:20210810T092706Z
LAST-MODIFIED:20211024T153947Z
UID:5826-1615489200-1615494600@kesho-kenya.org
SUMMARY:Renal Cell Carcinoma
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Caroline Tonio\, Consultant Physician\, and Medical Oncologist\, Muranga County Hospital\, Kenya. Sponsor: Roche Presenters: \n\nDr. David K. Kimani\, Consultant Surgeon\, and Urologist\, Kenyatta National Hospital\nDr. Manel Haj Mansour\, Consultant Physician\, and Medical Oncologist\, Aga Khan University Hospital\n\nKidney cancers account for 5% and 3% of all adult malignancies in men and women. It’s the 7th most common cancer in men and the 10th most common cancer in women. Renal cell carcinomas (RCC) account for 80% of kidney cancers with a median age of 64 years. The risk factors include lifestyle\, comorbidities\, environmental exposures\, and genetic factors. Protective factors include the use of alcohol and coffee. Renal masses are primary or secondary\, the majority of which are RCC while a few are transitional cell carcinomas.  RCC is mainly asymptomatic\, but the advanced disease has a range of symptoms. Mortality rates from RCC have remained stable or have decreased slightly in developed countries\, mainly due to timely screening and early diagnosis. The current imaging modalities cannot reliably distinguish benign and malignant tumors or between indolent and aggressive tumor biology.  Consequently\, renal mass biopsy (RMB) should be considered when a mass is suspected to be hematologic\, metastatic\, inflammatory\, or infectious\, as they have a high sensitivity\, specificity\, and positive predictive value. The non-diagnostic rate of RMB can be reduced by a repeat biopsy. There is no specific molecular marker recommended for clinical prognostic use. Management of small renal masses is by active surveillance\, nephron-sparing surgeries\, ablative and radical therapies. Partial nephrectomy prioritizes the preservation of renal functions through optimum salvage of nephrons. Priority should be to maintain negative surgical margins and to avoid the possibility of positive surgical margins with a probability of local recurrence.  For complex tumors where partial nephrectomy is challenging\, radical nephrectomy is recommended. This involves the removal of the entire kidney with or without the adrenal gland and the lymph nodes. To remove the adrenal gland or not depends on findings of metastasis or direct invasion of the adrenal gland. The involvement of the adrenal gland is associated with a poor prognosis. In patients undergoing surgical excision of a renal mass\, a minimally invasive approach should be considered when it would not compromise oncologic\, functional\, and perioperative outcomes. Since RCC is radioresistant\, radiotherapy can only be used for palliative treatment. Systemic therapy should be prioritized over cytoreductive nephrectomy for patients with metastatic RCC.  First-line treatment is different for the good or intermediate and the poor-risk groups. Currently\, there is a paradigm shift to the use of immunotherapy treatment and immune checkpoint inhibitors. However\, the high cost of drugs and the fact that the National Hospital Insurance Fund (NHIF) may not cover the entire costs\, complicates effective treatment.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/renal-cell-carcinoma/
CATEGORIES:CME 2021,Webinar Recording Available
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/08/885d0987-01df-49cb-99df-b91ddfefd49d.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20210223T190000
DTEND;TZID=Africa/Nairobi:20210223T203000
DTSTAMP:20260424T071254
CREATED:20210810T094424Z
LAST-MODIFIED:20211024T153955Z
UID:5831-1614106800-1614112200@kesho-kenya.org
SUMMARY:Management of Advanced Prostate Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Ahmed Komen \nSponsor: Beacon \nPresenters: \n\nProf. Asim Jamal Shaikh\, Associate professor of Medicine\, Consultant Medical Oncologist\, Aga Khan Hospital\, Nairobi\n\nProstate cancer is the most common cancer in Kenyan men\, where 80% of patients present with advanced disease\, encompassing a broad spectrum of diseases. The disease can be metastatic or non-metastatic. Metastatic hormone-sensitive prostate cancer is diagnosed by serum total PSA\, a biopsy\, conventional imaging (not readily available in Kenya)\, and Next-Generation Imaging (NGI).  NGI is useful in grouping the patients as high/low risk/volume\, depending on the disease burden. The Kenya national cancer screening guidelines guide the screening process\, which should be individualized with consultations between the physician and the patient. Management of Metastatic hormone-sensitive prostate cancer is by androgen deprivation therapy (ADT)\, achieved through surgical or medical castration. ADT should be started within 3 months of diagnosis. Advanced prostate cancer in patients who are hormone-sensitive or with high risk/volume requires a combination of ADT and chemotherapy treatment for a better outcome\, where disease volume or aggressiveness may help tailor treatment selection.  The addition of surgery and /or radiotherapy to systemic treatment may have a role in the treatment of newly diagnosed metastatic disease. Radiation therapy has a significant role in palliative treatment settings. Management of other histological subtypes of prostate cancer requires a histology review since the different subtypes are treated differently. Some patients transform from adenocarcinoma to neuroendocrine subtype hence may require ADT. However\, the degree of differentiation should be put into consideration. Prognosis is relatively poor\, hence it’s important to perform a pathology review in case the patient is not responding well to treatment. Prostate treatment affects a patient’s sexuality\, but ADT and vacuum-assisted devices help to restore sexual function. Considering the high cost of treatment\, chemotherapy and the use of generic forms of the drugs may be quite affordable.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-advanced-prostate-cancer/
CATEGORIES:CME 2021,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210811_134639.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20210218T190000
DTEND;TZID=Africa/Nairobi:20210218T203000
DTSTAMP:20260424T071254
CREATED:20210810T100615Z
LAST-MODIFIED:20211024T154003Z
UID:5837-1613674800-1613680200@kesho-kenya.org
SUMMARY:Molecular Testing For Breast Cancer and Implications For Treatment
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Peter Oyiro\, Medical Oncologist Kenyatta National Hospital Teaching and Referral Hospital \nSponsor: Beacon \nPresenters: \n\nDr. Sitna Mwanzi\, Consultant Physician and Medical Oncologist\, Aga Khan Hospital\, Nairobi\n\nBreast cancer is the most common type of cancer with 6799 new cases and 3107 death in Kenya in 2020. The mean age is 45-51 years. Molecular signature by microarray and immunohistochemistry has classified four molecular subtypes of breast cancer as including luminal A\, luminal B\, HER2+\, triple-negative breast cancer (TNBC)\, where luminal A and B are the most common molecular signatures  The molecular profiles are important prognostic and predictive factors in breast cancer. Luminal A has a better prognosis followed by luminal B\, hence patients with these subtypes are likely to be treated with surgery with or without adjuvant radiation therapy. HER2+ has a worse prognosis followed by TNBC\, hence patients with these subtypes will require chemotherapy and neoadjuvant. Genetic testing can be recommended in a case where a family member has a known pathogenic variant\, or in case of a personal history of breast cancer under the age of 45 years or within 45-60 years.  Additionally\, genetic testing is recommended in a new diagnosis of metastatic breast cancer\, and for young patients TNBC. Management for patients with BRCA pathogenic variant involves continued screening using mammography with tomosynthesis (digital mammography) and discussion on the risk reduction mastectomy and salpingo-oophorectomy. Relatives of such patients should be counseled on screening for pathogenic variants and if possible\, they should receive breast cancer screening at the age of 24-29 years\, and the screening should be done annually. The major challenges of genetic testing in Kenya include a lack of technical expertise and a shortage of genetic counselors\, to address the ethical concerns surrounding genetic counseling.  The tests are unavailable in many health care facilities. Furthermore\, the tests are not affordable\, since the samples have to be shipped to the USA for analysis. Traditionally\, the choice of adjuvant therapy was dependent on tumor size\, nodal status\, receptor status\, tumor grade\, age of the patient (younger patients were more likely to receive adjuvant chemotherapy). However\, more recent understanding has revealed that not all node-negative hormone receptor-positive patients benefit from chemotherapy.  Newer gene expression assays are helpful in tailoring treatment to avoid over and under-treatment.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/molecular-testing-for-breast-cancer-and-implications-for-treatment/
CATEGORIES:CME 2021,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210811_132829.jpg
END:VEVENT
END:VCALENDAR